Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nafcillin
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
Nafcillin is a semi-synthetic, beta-lactamase-resistant penicillin antibiotic used primarily to treat infections caused by susceptible staphylococcal bacteria, especially those resistant to other penicillins but not methicillin-resistant Staphylococcus aureus (MRSA)[2][4][5]. It acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), thereby blocking the final transpeptidation step of peptidoglycan synthesis and leading to cell lysis and death[2][6][8]. Nafcillin is indicated for bacteremia, skin and soft tissue infections, respiratory tract infections, bone and joint infections, urinary tract infections (UTIs), and endocarditis caused by susceptible organisms[1][4][5]. It is administered intravenously or intramuscularly. Nafcillin was developed as a narrow-spectrum antistaphylococcal agent with high resistance to inactivation by staphylococcal penicillinase[2].
- Brand names
- NafcilNallpenUnipen
- Other names
- nafcillin sodiumnafcillin sodium salt monohydrate
02
Targets
PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on nafcillin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nafcillin.